Yu-Sheng Cong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yu-Sheng Cong has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
Miao Wang
Zhejiang Key Laboratory of Medical Epigenetics, School of Basic Medical Sciences, Key Laboratory of Aging and Cancer Biology of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, China
21 shared publicationsJunzhi Zhou
Key Laboratory of Aging and Cancer Biology of Zhejiang Province, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou, China
12 shared publicationsLu Xu
Key Laboratory of Aging and Cancer Biology of Zhejiang Province, Hangzhou Normal University School of Nursing, Hangzhou, China
10 shared publicationsQian Liang
Zhejiang Key Laboratory of Medical Epigenetics, School of Basic Medical Sciences, Key Laboratory of Aging and Cancer Biology of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, China
8 shared publicationsJian Mao
Key Laboratory of Aging and Cancer Biology of Zhejiang Province, School of Basic Medical Sciences, College of Life and Environmental Science, Hangzhou Normal University, Hangzhou, China
7 shared publicationsQian Zhang
Zhejiang Key Laboratory of Medical Epigenetics, Zhejiang Key Laboratory of Aging and Cancer Biology Hangzhou Normal University School of Basic Medical Sciences Hangzhou China
7 shared publications
Latest Publications
- Open Access
- 8 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 10014
TRIM26-Mediated Ubiquitination and Degradation of DDRGK1 Suppress NSCLC Progression by Inhibiting DNA Repair and Promoting Apoptosis
The high incidence and poor prognosis of non-small-cell lung cancer (NSCLC) underscore the urgent need to elucidate the molecular mechanisms underlying its progression and chemoresistance. Here, we investigated the role of DDRGK domain-containing protein 1 (DDRGK1) in NSCLC and identified a novel regulatory axis governing its protein stability. Clinically, DDRGK1 was markedly upregulated in NSCLC tissues, and elevated DDRGK1 expression correlated with advanced tumor stage, poor overall survival, and chemoresistance. Functionally, DDRGK1 knockout significantly suppressed NSCLC cell growth, an effect reversed by DDRGK1 re-expression. Mechanistically, tripartite motif-containing protein 26 (TRIM26) was identified as the E3 ubiquitin ligase that catalyzed K48-linked polyubiquitination of DDRGK1 at K267, promoting its degradation. This modification antagonized E3 UFM1-protein ligase 1 (UFL1)-mediated UFMylation at the same residue, thereby fine-tuning DDRGK1 stability. Functional enrichment analysis showed that DDRGK1-interacting proteins and proteins differentially expressed in DDRGK1-knockout cells were predominantly associated with the DNA damage response and apoptosis. Consistently, DDRGK1 knockout suppressed ATR phosphorylation and augmented cisplatin-induced apoptosis in NSCLC cells. Collectively, these findings define the regulatory mechanism of DDRGK1, establish it as a key regulator of NSCLC progression, and highlight its potential as a therapeutic target for overcoming chemoresistance.
- 8 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 10014
Open AccessTRIM26-Mediated Ubiquitination and Degradation of DDRGK1 Suppress NSCLC Progression by Inhibiting DNA Repair and Promoting Apoptosis
The high incidence and poor prognosis of non-small-cell lung cancer (NSCLC) underscore the urgent need to elucidate the molecular mechanisms underlying its progression and chemoresistance. Here, we investigated the role of DDRGK domain-containing protein 1 (DDRGK1) in NSCLC and identified a novel regulatory axis governing its protein stability. Clinically, DDRGK1 was markedly upregulated in NSCLC tissues, and elevated DDRGK1 expression correlated with advanced tumor stage, poor overall survival, and chemoresistance. Functionally, DDRGK1 knockout significantly suppressed NSCLC cell growth, an effect reversed by DDRGK1 re-expression. Mechanistically, tripartite motif-containing protein 26 (TRIM26) was identified as the E3 ubiquitin ligase that catalyzed K48-linked polyubiquitination of DDRGK1 at K267, promoting its degradation. This modification antagonized E3 UFM1-protein ligase 1 (UFL1)-mediated UFMylation at the same residue, thereby fine-tuning DDRGK1 stability. Functional enrichment analysis showed that DDRGK1-interacting proteins and proteins differentially expressed in DDRGK1-knockout cells were predominantly associated with the DNA damage response and apoptosis. Consistently, DDRGK1 knockout suppressed ATR phosphorylation and augmented cisplatin-induced apoptosis in NSCLC cells. Collectively, these findings define the regulatory mechanism of DDRGK1, establish it as a key regulator of NSCLC progression, and highlight its potential as a therapeutic target for overcoming chemoresistance.
- Open Access
- 22 June 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (9) , 113285
UFMylation orchestrates kidney development through YAP stabilization
- 22 June 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (9) , 113285
Open AccessUFMylation orchestrates kidney development through YAP stabilization
- Open Access
- 25 February 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (4) , 111320
Optimization of protein UFMylation modification method and its application in substrate identification in human cells
- 25 February 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (4) , 111320
Open AccessOptimization of protein UFMylation modification method and its application in substrate identification in human cells
- Open Access
- 25 January 2026
- Published by Elsevier in Redox Biology
- Vol. 90, 104046
UFMylation deficiency in hepatocytes activates the KEAP1-NRF2 pathway and contributes to hepatocarcinogenesis
- 25 January 2026
- Published by Elsevier in Redox Biology
- Vol. 90, 104046
Open AccessUFMylation deficiency in hepatocytes activates the KEAP1-NRF2 pathway and contributes to hepatocarcinogenesis
- Open Access
- 31 July 2025
- Published by Wiley in Cell Proliferation
- Vol. 59 (2) , e70086
PTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFR
Melanoma is the most serious type of skin cancer. About half of all melanomas have activating BRAF mutations. Targeted therapy for malignant melanoma with BRAF inhibitor (BRAFi) or its combination with MEK inhibitor (MEKi) improves the clinical outcomes of patients, but resistance develops invariably. The underlying mechanisms remain incompletely understood. Here, we show that caveolae number is increased in both BRAFi and BRAFi + MEKi‐resistant melanoma cells, and the expression of the critical caveolae component PTRF is significantly upregulated in drug‐resistant melanoma cell lines and tumour tissues. Knockdown of PTRF in drug‐resistant cells reduces proliferation with increased apoptosis, whereas ectopic expression of PTRF confers resistance on parental cells to BRAFi or BRAFi + MEKi. On the contrary, the knockdown of PTRF in parental cells reduces their ability to acquire drug resistance induced by BRAFi treatment. Interestingly, we find that the expression of EGFR is increased along with PTRF and caveolin‐1 in drug‐resistant cells and in PTRF transduced parental cells, whereas knockdown of PTRF results in down‐regulation of EGFR expression and attenuates drug resistance of parental cells induced by PTRF expression. Together, these results suggest that PTRF contributes to therapy resistance through upregulating EGFR in melanoma cells.
- 31 July 2025
- Published by Wiley in Cell Proliferation
- Vol. 59 (2) , e70086
Open AccessPTRF Confers Melanoma‐Acquired Drug Resistance Through the Upregulation of EGFR
Melanoma is the most serious type of skin cancer. About half of all melanomas have activating BRAF mutations. Targeted therapy for malignant melanoma with BRAF inhibitor (BRAFi) or its combination with MEK inhibitor (MEKi) improves the clinical outcomes of patients, but resistance develops invariably. The underlying mechanisms remain incompletely understood. Here, we show that caveolae number is increased in both BRAFi and BRAFi + MEKi‐resistant melanoma cells, and the expression of the critical caveolae component PTRF is significantly upregulated in drug‐resistant melanoma cell lines and tumour tissues. Knockdown of PTRF in drug‐resistant cells reduces proliferation with increased apoptosis, whereas ectopic expression of PTRF confers resistance on parental cells to BRAFi or BRAFi + MEKi. On the contrary, the knockdown of PTRF in parental cells reduces their ability to acquire drug resistance induced by BRAFi treatment. Interestingly, we find that the expression of EGFR is increased along with PTRF and caveolin‐1 in drug‐resistant cells and in PTRF transduced parental cells, whereas knockdown of PTRF results in down‐regulation of EGFR expression and attenuates drug resistance of parental cells induced by PTRF expression. Together, these results suggest that PTRF contributes to therapy resistance through upregulating EGFR in melanoma cells.
- Open Access
- 1 January 2025
- Published by Tech Science Press in Oncology Research
- Vol. 33 (11) , 3231-3245
The Role of UFMylation in the Development and Progression of Gastric Cancer
Gastric Cancer (GC) is a highly prevalent and poorly prognostic gastrointestinal malignancy with low overall treatment efficacy worldwide. Early diagnostic markers and potential therapeutic targets for GC treatment are urgently needed. UFMylation, a novel ubiquitin-like modification is indispensable for numerous fundamental cellular processes. Deficiency in this modification is reported to be associated with several human diseases including cancer. Accumulating evidence suggests that the expression of the key UFMylation components is closely associated with GC cell proliferation, invasion, metastasis, and chemotherapy resistance. Recent clinical studies have further highlighted the prognostic value and therapeutic potential of UFMylation in the clinical management of GC. However, the precise molecular mechanisms through which UFMylation contributes to GC remain largely unclear. This review aims to summarize recent findings on the functional roles of UFMylation in diverse cellular processes, such as endoplasmic reticulum (ER) homeostasis, DNA damage response (DDR), protein translation, and quality control pathways, discuss potential underlying mechanisms in GC development and progression, and to explore potential therapeutic implications targeting the UFMylation pathway in GC.
- 1 January 2025
- Published by Tech Science Press in Oncology Research
- Vol. 33 (11) , 3231-3245
Open AccessThe Role of UFMylation in the Development and Progression of Gastric Cancer
Gastric Cancer (GC) is a highly prevalent and poorly prognostic gastrointestinal malignancy with low overall treatment efficacy worldwide. Early diagnostic markers and potential therapeutic targets for GC treatment are urgently needed. UFMylation, a novel ubiquitin-like modification is indispensable for numerous fundamental cellular processes. Deficiency in this modification is reported to be associated with several human diseases including cancer. Accumulating evidence suggests that the expression of the key UFMylation components is closely associated with GC cell proliferation, invasion, metastasis, and chemotherapy resistance. Recent clinical studies have further highlighted the prognostic value and therapeutic potential of UFMylation in the clinical management of GC. However, the precise molecular mechanisms through which UFMylation contributes to GC remain largely unclear. This review aims to summarize recent findings on the functional roles of UFMylation in diverse cellular processes, such as endoplasmic reticulum (ER) homeostasis, DNA damage response (DDR), protein translation, and quality control pathways, discuss potential underlying mechanisms in GC development and progression, and to explore potential therapeutic implications targeting the UFMylation pathway in GC.
- 14 November 2024
- Published by Springer Nature in Nature Aging
- Vol. 4 (12) , 1794-1812
Reactivation of senescence-associated endogenous retroviruses by ATF3 drives interferon signaling in aging
Reactivation of endogenous retroviruses (ERVs) has been proposed to be involved in aging. However, the mechanism of reactivation and contribution to aging and age-associated diseases is largely unexplored. In this study, we identified a subclass of ERVs reactivated in senescent cells (termed senescence-associated ERVs (SA-ERVs)). These SA-ERVs can be bidirectional transcriptionally activated by activating transcription factor 3 (ATF3) to generate double-stranded RNAs (dsRNAs), which activate the RIG-I/MDA5–MAVS signaling pathway and trigger a type I interferon (IFN-I) response in senescent fibroblasts. Consistently, we found a concerted increased expression of ATF3 and SA-ERVs and enhanced IFN-I response in several tissues of healthy aged individuals and patients with Hutchinson–Gilford progeria syndrome. Moreover, we observed an accumulation of dsRNAs derived from SA-ERVs and higher levels of IFNβ in blood of aged individuals. Together, these results reveal a previously unknown mechanism for reactivation of SA-ERVs by ATF3 and illustrate SA-ERVs as an important component and hallmark of aging.
- 14 November 2024
- Published by Springer Nature in Nature Aging
- Vol. 4 (12) , 1794-1812
Reactivation of senescence-associated endogenous retroviruses by ATF3 drives interferon signaling in aging
Reactivation of endogenous retroviruses (ERVs) has been proposed to be involved in aging. However, the mechanism of reactivation and contribution to aging and age-associated diseases is largely unexplored. In this study, we identified a subclass of ERVs reactivated in senescent cells (termed senescence-associated ERVs (SA-ERVs)). These SA-ERVs can be bidirectional transcriptionally activated by activating transcription factor 3 (ATF3) to generate double-stranded RNAs (dsRNAs), which activate the RIG-I/MDA5–MAVS signaling pathway and trigger a type I interferon (IFN-I) response in senescent fibroblasts. Consistently, we found a concerted increased expression of ATF3 and SA-ERVs and enhanced IFN-I response in several tissues of healthy aged individuals and patients with Hutchinson–Gilford progeria syndrome. Moreover, we observed an accumulation of dsRNAs derived from SA-ERVs and higher levels of IFNβ in blood of aged individuals. Together, these results reveal a previously unknown mechanism for reactivation of SA-ERVs by ATF3 and illustrate SA-ERVs as an important component and hallmark of aging.
- Open Access
- 9 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
Recent development of new immune checkpoint inhibitors has been particularly successfully in cancer treatment, but still the majority patients fail to benefit. Converting resistant tumors to immunotherapy sensitive will provide a significant improvement in patient outcome. Here we identify Mi-2β as a key melanoma-intrinsic effector regulating the adaptive anti-tumor immune response. Studies in genetically engineered mouse melanoma models indicate that loss of Mi-2β rescues the immune response to immunotherapy in vivo. Mechanistically, ATAC-seq analysis shows that Mi-2β controls the accessibility of IFN-γ-stimulated genes (ISGs). Mi-2β binds to EZH2 and promotes K510 methylation of EZH2, subsequently activating the trimethylation of H3K27 to inhibit the transcription of ISGs. Finally, we develop an Mi-2β-targeted inhibitor, Z36-MP5, which reduces Mi-2β ATPase activity and reactivates ISG transcription. Consequently, Z36-MP5 induces a response to immune checkpoint inhibitors in otherwise resistant melanoma models. Our work provides a potential therapeutic strategy to convert immunotherapy resistant melanomas to sensitive ones.
- 9 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Open AccessMi-2β promotes immune evasion in melanoma by activating EZH2 methylation
Recent development of new immune checkpoint inhibitors has been particularly successfully in cancer treatment, but still the majority patients fail to benefit. Converting resistant tumors to immunotherapy sensitive will provide a significant improvement in patient outcome. Here we identify Mi-2β as a key melanoma-intrinsic effector regulating the adaptive anti-tumor immune response. Studies in genetically engineered mouse melanoma models indicate that loss of Mi-2β rescues the immune response to immunotherapy in vivo. Mechanistically, ATAC-seq analysis shows that Mi-2β controls the accessibility of IFN-γ-stimulated genes (ISGs). Mi-2β binds to EZH2 and promotes K510 methylation of EZH2, subsequently activating the trimethylation of H3K27 to inhibit the transcription of ISGs. Finally, we develop an Mi-2β-targeted inhibitor, Z36-MP5, which reduces Mi-2β ATPase activity and reactivates ISG transcription. Consequently, Z36-MP5 induces a response to immune checkpoint inhibitors in otherwise resistant melanoma models. Our work provides a potential therapeutic strategy to convert immunotherapy resistant melanomas to sensitive ones.
- Open Access
- 1 January 2024
- Published by Biophysical Society of China in Biophysics Reports
- Vol. 9 (4) , 230-240
Met1-linked ubiquitination in cell signaling regulation
Met1-linked ubiquitination (Met1-Ub), also known as linear ubiquitination, is a newly identified atypical type of polyubiquitination that is assembled via the N-terminal methionine (Met1) rather than an internal lysine (Lys) residue of ubiquitin. The linear ubiquitin chain assembly complex (LUBAC) composed of HOIP, HOIL-1L and SHARPIN is the sole E3 ubiquitin ligase that specifically generates Met1-linked ubiquitin chains. The physiological role of LUBAC-mediated Met1-Ub has been first described as activating NF-κB signaling through the Met1-Ub modification of NEMO. However, accumulating evidence shows that Met1-Ub is broadly involved in other cellular pathways including MAPK, Wnt/β-Catenin, PI3K/AKT and interferon signaling, and participates in various cellular processes including angiogenesis, protein quality control and autophagy, suggesting that Met1-Ub harbors a potent signaling capacity. Here, we review the formation and cellular functions of Met1-linked ubiquitin chains, with an emphasis on the recent advances in the cellular mechanisms by which Met1-Ub controls signaling transduction.
- 1 January 2024
- Published by Biophysical Society of China in Biophysics Reports
- Vol. 9 (4) , 230-240
Open AccessMet1-linked ubiquitination in cell signaling regulation
Met1-linked ubiquitination (Met1-Ub), also known as linear ubiquitination, is a newly identified atypical type of polyubiquitination that is assembled via the N-terminal methionine (Met1) rather than an internal lysine (Lys) residue of ubiquitin. The linear ubiquitin chain assembly complex (LUBAC) composed of HOIP, HOIL-1L and SHARPIN is the sole E3 ubiquitin ligase that specifically generates Met1-linked ubiquitin chains. The physiological role of LUBAC-mediated Met1-Ub has been first described as activating NF-κB signaling through the Met1-Ub modification of NEMO. However, accumulating evidence shows that Met1-Ub is broadly involved in other cellular pathways including MAPK, Wnt/β-Catenin, PI3K/AKT and interferon signaling, and participates in various cellular processes including angiogenesis, protein quality control and autophagy, suggesting that Met1-Ub harbors a potent signaling capacity. Here, we review the formation and cellular functions of Met1-linked ubiquitin chains, with an emphasis on the recent advances in the cellular mechanisms by which Met1-Ub controls signaling transduction.